
Michigan-based software company and stealth-mode biotech firm, Sendero Biotechnology.
Founded in partnership with Mayo Clinic, Sendero Biotechnology is a Michigan-based biotechnology company focused on developing novel oncology therapies. The company's core mission is to advance cancer treatment by targeting the TRAIL pathway, specifically through therapies against the immune evasion target TRAILshort. By leveraging cutting-edge research and technology licensed from Dr. Andrew Badley's lab, Sendero aims to bring innovative solutions to the oncology market.
Notable affiliations include the prestigious Mayo Clinic and Dr. Andrew Badley, whose research underpins the company's technological advancements. Although operating in stealth mode, Sendero Biotechnology has made significant strides in the field of cancer therapy. Its impact lies in its potential to revolutionize cancer treatment by addressing immune evasion mechanisms, thereby improving patient outcomes and advancing the broader field of oncology.

Seneca Therapeutics

Exovita Biosciences

OncoResponse

Sporos Bioventures

Senda Biosciences

Novasenta
novasenta.com

Cartography Biosciences
cartography.bio

Trailhead Biosystems

Cadenza Bio
cadenza.bio

Strm.Bio
strm.bio

Camino Pharma
caminopharma.com

Treadwell Therapeutics
treadwelltx.com

OncoTrap

Sentien Biotechnologies

Inceptor Bio
inceptor.bio
Companies similar to Sendero Biotechnology include Seneca Therapeutics, Exovita Biosciences, OncoResponse and Sporos Bioventures.
Sendero Biotechnology was founded in 2021.
Sendero Biotechnology's headquarters is located in Rochester, MI, US.
Sendero Biotechnology's most recent funding round was for $7.3M (USD) in April 2023.
As of Apr 28, 2023, Sendero Biotechnology has raised a total of $7.3M (USD).
Sendero Biotechnology has 50 employees as of Feb 5, 2024.